Cyclic AMP can promote APL progression and protect myeloid leukemia cells against anthracycline-induced apoptosis

Cell Death and Disease

Volumn 4, Issue 2, 2013, Pages

  Gausdal, G ^a   Wergeland, A ^a   Skavland, J ^a   Nguyen, E ^b,c   Pendino, F ^b,c   Rouhee, N ^a   McCormack, E ^a   Herfindal, L ^a,d   Kleppe, R ^a   Havemann, U ^e   Schwede, F ^e   Bruserud, O ^a,d   Gjertsen, B T ^a,d   Lanotte, M ^b,c   Segal Bendirdjian E ^b,c   Doskeland S O ^a  

^a UNIVERSITY OF BERGEN   (Norway)

^b INSERM   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^e BIOLOG Life Science Institute   (Germany)

Author keywords

ATRA; Bad; BH3; CREB; NB4; PKA

Indexed keywords

CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE 1; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DAUNORUBICIN; DEOXYGLUCOSE; PROSTAGLANDIN E2; PROTEASOME INHIBITOR; RETINOIC ACID; ROTENONE; SERINE; THEOPHYLLINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CELL DEATH; CELL DIFFERENTIATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOPLASM; DISEASE COURSE; IN VITRO STUDY; LEUKEMIA CELL; MALE; MOUSE; MYELOID LEUKEMIA; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN PHOSPHORYLATION; TREATMENT FAILURE;

1-METHYL-3-ISOBUTYLXANTHINE; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BCL-ASSOCIATED DEATH PROTEIN; CELL LINE, TUMOR; CYCLIC AMP; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYCLIC AMP-DEPENDENT PROTEIN KINASE TYPE I; CYCLIC AMP-DEPENDENT PROTEIN KINASE TYPE II; DAUNORUBICIN; DINOPROSTONE; DISEASE PROGRESSION; HL-60 CELLS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MICE; MICE, INBRED NOD; MICE, SCID; RNA INTERFERENCE; RNA, SMALL INTERFERING; THEOPHYLLINE; TRANSPLANTATION, HETEROLOGOUS; TRETINOIN;

MUS;

EID: 84876011662     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.39     Document Type: Article

References (50)

1. Bos JL. Epac proteins: multi-purpose cAMP targets. Trends Biochem Sci 2006; 31: 680-686.
2. Kopperud R, Krakstad C, Selheim F, Doskeland SO. cAMP effector mechanisms. Novel twists for an 'old' signaling system. FEBS Lett 2003; 546: 121-126.
3. Ruchaud S, Duprez E, Gendron MC, Houge G, Genieser HG, Jastorff B et al. Two distinctly regulated events, priming and triggering, during retinoid-induced maturation and resistance of NB4 promyelocytic leukemia cell line. Proc Natl Acad Sci USA 1994; 91: 8428-8432.
4. Habib A, Hamade E, Mahfouz R, Nasrallah MS, de The H, Bazarbachi A. Arsenic trioxide inhibits ATRA-induced prostaglandin E2 and cyclooxygenase-1 in NB4 cells, a model of acute promyelocytic leukemia. Leukemia 2008; 22: 1125-1130.
5. Roussel MJ, Lanotte M. Maturation sensitive and resistant t(15;17) NB4 cell lines as tools for APL physiopathology: nomenclature of cells and repertory of their known genetic alterations and phenotypes. Oncogene 2001; 20: 7287-7291.
6. Parrella E, Gianni M, Cecconi V, Nigro E, Barzago MM, Rambaldi A et al. Phosphodiesterase IV inhibition by piclamilast potentiates the cytodifferentiating action of retinoids in myeloid leukemia cells. Cross-talk between the cAMP and the retinoic acid signaling pathways. J Biol Chem 2004; 279: 42026-42040.
7. Guillemin MC, Raffoux E, Vitoux D, Kogan S, Soilihi H, Lallemand-Breitenbach V et al. In vivo activation of cAMP signaling induces growth arrest and differentiation in acute promyelocytic leukemia. J Exp Med 2002; 196: 1373-1380.
8. Nasr R, Guillemin MC, Ferhi O, Soilihi H, Peres L, Berthier C et al. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat Med 2008; 14: 1333-1342.
9. Fox S, Leitch AE, Duffin R, Haslett C, Rossi AG. Neutrophil apoptosis: relevance to the innate immune response and inflammatory disease. J Innate Immun 2010; 2: 216-227.
10. Krakstad C, Christensen AE, Doskeland SO. cAMP protects neutrophils against TNF- {alpha}-induced apoptosis by activation of cAMP-dependent protein kinase, independently of exchange protein directly activated by cAMP (Epac). J Leukoc Biol 2004; 76: 641-647.
11. Geering B, Simon HU. Peculiarities of cell death mechanisms in neutrophils. Cell Death Differ 2011; 18: 1457-1469.
12. Garcia-Bermejo L, Perez C, Vilaboa NE, de Blas E, Aller P. cAMP increasing agents attenuate the generation of apoptosis by etoposide in promonocytic leukemia cells. J Cell Sci 1998; 111(Pt 5): 637-644.
13. Huseby S, Gausdal G, Keen TJ, Kjaerland E, Krakstad C, Myhren L et al. Cyclic AMP induces IPC leukemia cell apoptosis via CRE-and CDK-dependent Bim transcription. Cell Death Dis 2011; 2: e237.
14. Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009; 113: 1875-1891.
15. Sanz MA, Montesinos P, Rayon C, Holowiecka A, de la Serna J, Milone G et al. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood 2010; 115: 5137-5146.
16. Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, Chaleff S et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 2005; 174: 6477-6489.
17. Gausdal G, Gjertsen BT, Fladmark KE, Demol H, Vandekerckhove J, Doskeland SO. Caspase-dependent, geldanamycin-enhanced cleavage of co-chaperone p23 in leukemic apoptosis. Leukemia 2004; 18: 1989-1996.
18. Pesic M, Podolski A, Rakic L, Ruzdijic S. Purine analogs sensitize the multidrug resistant cell line (NCI-H460/R) to doxorubicin and stimulate the cell growth inhibitory effect of verapamil. Invest New Drugs 2010; 28: 482-492.
19. Chandra P, Zhang P, Brouwer KL. Short-term regulation of multidrug resistanceassociated protein 3 in rat and human hepatocytes. Am J Physiol Gastrointest Liver Physiol 2005; 288: G1252-G1258.
20. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999; 57: 727-741.
21. Benito J, Shi Y, Szymanska B, Carol H, Boehm I, Lu H et al. Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104. PLoS One 6: e23108.
22. Burnett A, Wetzler M, Lowenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol 2011; 29: 487-494.
23. Christensen AE, Selheim F, de Rooij J, Dremier S, Schwede F, Dao KK et al. cAMP analog mapping of Epac1 and cAMP kinase. Discriminating analogs demonstrate that Epac and cAMP kinase act synergistically to promote PC-12 cell neurite extension. J Biol Chem 2003; 278: 35394-35402.
24. Skroblin P, Grossmann S, Schafer G, Rosenthal W, Klussmann E. Mechanisms of protein kinase A anchoring. Int Rev Cell Mol Biol 2010; 283: 235-330.
25. DiPilato LM, Cheng X, Zhang J. Fluorescent indicators of cAMP and Epac activation reveal differential dynamics of cAMP signaling within discrete subcellular compartments. Proc Natl Acad Sci USA 2004; 101: 16513-16518.
26. Gjertsen BT, Mellgren G, Otten A, Maronde E, Genieser HG, Jastorff B et al. Novel (Rp)-cAMPS analogs as tools for inhibition of cAMP-kinase in cell culture. Basal cAMP-kinase activity modulates interleukin-1 beta action. J Biol Chem 1995; 270: 20599-20607.
27. Naviglio S, Caraglia M, Abbruzzese A, Chiosi E, Di Gesto D, Marra M et al. Protein kinase A as a biological target in cancer therapy. Expert Opin Ther Targets 2009; 13: 83-92.
28. Datta SR, Katsov A, Hu L, Petros A, Fesik SW, Yaffe MB et al. 14-3-3 proteins and survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation. Mol Cell 2000; 6: 41-51.
29. Danial NN. BAD: undertaker by night, candyman by day. Oncogene 2008; 27(Suppl 1): S53-S70.
30. Shankar DB, Cheng JC, Kinjo K, Federman N, Moore TB, Gill A et al. The role of CREB as a proto-oncogene in hematopoiesis and in acute myeloid leukemia. Cancer Cell 2005; 7: 351-362.
31. Gonzalez GA, Montminy MR. Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at serine 133. Cell 1989; 59: 675-680.
32. Polzien L, Baljuls A, Rennefahrt UE, Fischer A, Schmitz W, Zahedi RP et al. Identification of novel in vivo phosphorylation sites of the human proapoptotic protein BAD: pore-forming activity of BAD is regulated by phosphorylation. J Biol Chem 2009; 284: 28004-28020.
33. Wang JL, Liu D, Zhang ZJ, Shan S, Han X, Srinivasula SM et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci USA 2000; 97: 7124-7129.
34. Irish JM, Hovland R, Krutzik PO, Perez OD, Bruserud O, Gjertsen BT et al. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell 2004; 118: 217-228.
35. Leitch AE, Lucas CD, Marwick JA, Duffin R, Haslett C, Rossi AG. Cyclin-dependent kinases 7 and 9 specifically regulate neutrophil transcription and their inhibition drives apoptosis to promote resolution of inflammation. Cell Death Differ 2012; 19: 1950-1961.
36. Zhou J, Bi C, Janakakumara JV, Liu SC, Chng WJ, Tay KG et al. Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML. Blood 2009; 113: 4052-4062.
37. Ekanger R, Sand TE, Ogreid D, Christoffersen T, Doskeland SO. The separate estimation of cAMP intracellularly bound to the regulatory subunits of protein kinase I and II in glucagon-stimulated rat hepatocytes. J Biol Chem 1985; 260: 3393-3401.
38. Naderi EH, Findley HW, Ruud E, Blomhoff HK, Naderi S. Activation of cAMP signaling inhibits DNA damage-induced apoptosis in BCP-ALL cells through abrogation of p53 accumulation. Blood 2009; 114: 608-618.
39. Kamimura T, Miyamoto T, Harada M, Akashi K. Advances in therapies for acute promyelocytic leukemia. Cancer Sci 2011; 102: 1929-1937.
40. Laurent G, Jaffrezou JP. Signaling pathways activated by daunorubicin. Blood 2001; 98: 913-924.
41. Gausdal G, Gjertsen BT, McCormack E, Van Damme P, Hovland R, Krakstad C et al. Abolition of stress-induced protein synthesis sensitizes leukemia cells to anthracyclineinduced death. Blood 2008; 111: 2866-2877.
42. Sakata D, Yao C, Narumiya S. Prostaglandin E2, an immunoactivator. J Pharmacol Sci 2010; 112: 1-5.
43. Doskeland SO, Maronde E, Gjertsen BT. The genetic subtypes of cAMP-dependent protein kinase - functionally different or redundant? Biochim Biophys Acta 1993; 1178: 249-258.
44. Mavrakis M, Lippincott-Schwartz J, Stratakis CA, Bossis I. mTOR kinase and the regulatory subunit of protein kinase A (PRKAR1A) spatially and functionally interact during autophagosome maturation. Autophagy 2007; 3: 151-153.
45. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9: 47-59.
46. Cho EC, Mitton B, Sakamoto KM. CREB and leukemogenesis. Crit Rev Oncog 2011; 16: 37-46.
47. Duprez E, Ruchaud S, Houge G, Martin-Thouvenin V, Valensi F, Kastner P et al. A retinoid acid 'resistant' t(15;17) acute promyelocytic leukemia cell line: isolation, morphological, immunological, and molecular features. Leukemia 1992; 6: 1281-1287.
48. Bruserud O, Gjertsen BT, Foss B, Huang TS. New strategies in the treatment of acute myelogenous leukemia (AML): in vitro culture of aml cells-the present use in experimental studies and the possible importance for future therapeutic approaches. Stem Cells 2001; 19: 1-11.
49. Moffat J, Grueneberg DA, Yang X, Kim SY, Kloepfer AM, Hinkle G et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 2006; 124: 1283-1298.
50. Pendino F, Nguyen E, Jonassen I, Dysvik B, Azouz A, Lanotte M et al. Functional involvement of RINF, retinoid-inducible nuclear factor (CXXC5), in normal and tumoral human myelopoiesis. Blood 2009; 113: 3172-3181.